LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell proliferation, survival, apoptosis, scattering and motility, invasion, and angiogenesis. MET over-expression (with or without gene amplification), aberrant a...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Yan, S. Betty, Peek, Victoria L., Ajamie, Rose, Buchanan, Sean G., Graff, Jeremy R., Heidler, Steven A., Hui, Yu-Hua, Huss, Karen L., Konicek, Bruce W., Manro, Jason R., Shih, Chuan, Stewart, Julie A., Stewart, Trent R., Stout, Stephanie L., Uhlik, Mark T., Um, Suzane L., Wang, Yong, Wu, Wenjuan, Yan, Lei, Yang, Wei J., Zhong, Boyu, Walgren, Richard A.
Формат: Artigo
Язык:Inglês
Опубликовано: Springer US 2012
Предметы:
Preclinical Studies
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3717159/
https://ncbi.nlm.nih.gov/pubmed/23275061
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-012-9912-9
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы